ATE80660T1 - Verfahren zur herstellung eines polypeptides. - Google Patents

Verfahren zur herstellung eines polypeptides.

Info

Publication number
ATE80660T1
ATE80660T1 AT87902674T AT87902674T ATE80660T1 AT E80660 T1 ATE80660 T1 AT E80660T1 AT 87902674 T AT87902674 T AT 87902674T AT 87902674 T AT87902674 T AT 87902674T AT E80660 T1 ATE80660 T1 AT E80660T1
Authority
AT
Austria
Prior art keywords
pct
polypeptide
secretion sequence
production
terminal secretion
Prior art date
Application number
AT87902674T
Other languages
English (en)
Inventor
Ian Barry Holland
Nigel Mackman
Jean-Marc Nicaud
Original Assignee
Ian Barry Holland
Nigel Mackman
Nicaud Jean Marc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ian Barry Holland, Nigel Mackman, Nicaud Jean Marc filed Critical Ian Barry Holland
Application granted granted Critical
Publication of ATE80660T1 publication Critical patent/ATE80660T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C12N9/6481—Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT87902674T 1986-05-15 1987-05-14 Verfahren zur herstellung eines polypeptides. ATE80660T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB868611832A GB8611832D0 (en) 1986-05-15 1986-05-15 Polypeptide
PCT/GB1987/000331 WO1987006953A1 (en) 1986-05-15 1987-05-14 Process for the production of a polypeptide
EP87902674A EP0267224B1 (de) 1986-05-15 1987-05-14 Verfahren zur herstellung eines polypeptides

Publications (1)

Publication Number Publication Date
ATE80660T1 true ATE80660T1 (de) 1992-10-15

Family

ID=10597902

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87902674T ATE80660T1 (de) 1986-05-15 1987-05-14 Verfahren zur herstellung eines polypeptides.

Country Status (9)

Country Link
US (1) US5143830A (de)
EP (1) EP0267224B1 (de)
JP (1) JPS63503274A (de)
AT (1) ATE80660T1 (de)
AU (1) AU600949B2 (de)
DE (1) DE3781765T2 (de)
DK (1) DK13788A (de)
GB (2) GB8611832D0 (de)
WO (1) WO1987006953A1 (de)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US5037743A (en) * 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US6210948B1 (en) 1992-06-09 2001-04-03 The University Of British Columbia Expression and secretion of heterologous polypeptides from caulobacter
US5914254A (en) * 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
US5563046A (en) * 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US6057091A (en) * 1994-12-02 2000-05-02 The Johns Hopkins University School Of Medicine Method of identifying compounds affecting hedgehog cholesterol transfer
US6214794B1 (en) 1994-12-02 2001-04-10 The Johns Hopkins University School Of Medicine Method of using hedgehog polypeptides to regulate neuronal cell growth
US6281332B1 (en) * 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
US6911528B1 (en) 1994-12-02 2005-06-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
HU226219B1 (en) * 1996-05-31 2008-06-30 Intervet Int Bv Live attenuated rtx-producing bacteria of the family pasteurellaceae
UA75316C2 (uk) 1996-10-16 2006-04-17 Займодженетікс, Інк. Гомологи з фактором росту фібробласта
US6036953A (en) * 1996-11-29 2000-03-14 The General Hospital Corporation Heterologous antigens in live cell V. cholerae strains
AU726423B2 (en) 1997-03-24 2000-11-09 Zymogenetics Inc. Motilin homologs
EP2284272B1 (de) 1998-06-10 2014-08-13 Novozymes A/S Mannanasen
CZ20011026A3 (cs) 1998-09-23 2001-08-15 Zymogenetics, Inc. Izolovaný polynukleotid, expresní vektor, kultivovaná buňka, konstrukt DNA, způsob produkce proteinu, izolovaný polypeptid, způsob produkce protilátky, protilátka a způsob detekce
DE69939330D1 (de) 1998-12-07 2008-09-25 Zymogenetics Inc Wachstumsfaktor-homologe zvegf-3
CZ303272B6 (cs) 1999-01-07 2012-07-11 Zymogenetics, Inc. Farmaceutický prostredek obsahující fúzní protein, izolovaná molekula polynukleotidu, expresní vektor, kultivovaná bunka, zpusob prípravy polypeptidu a izolovaný polypeptid
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
CA2261186A1 (en) 1999-02-19 2000-08-19 University Of British Columbia Expression and secretion of heterologous polypeptides from freshwater caulobacter
UA84387C2 (ru) 1999-03-09 2008-10-27 Займодженетикс, Инк. Человеческий цитокин как лиганд зальфа рецептора и его применение
US6664386B1 (en) 1999-04-08 2003-12-16 The Research Foundation Of State University Of New York System for efficient secretion of recombinant proteins
DE60034564T2 (de) 1999-07-07 2007-12-27 Zymogenetics, Inc., Seattle Menschlicher cytokinrezeptor
US7304151B2 (en) 1999-12-17 2007-12-04 University Of Guelph Modified leukotoxin gene and protein
EP2194130A1 (de) 1999-12-23 2010-06-09 ZymoGenetics, L.L.C. Zytokin ZCYT018
ES2279809T3 (es) 2000-04-05 2007-09-01 Zymogenetics, Inc. Receptores de citoquina zalfa11 solubles.
EP1325115B1 (de) 2000-06-26 2016-07-27 ZymoGenetics, Inc. Cytokinrezeptor zcytor17
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US7795002B2 (en) * 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
ES2286128T3 (es) 2000-06-30 2007-12-01 Zymogenetics, Inc. Proteina zcyto21 tipo interferon.
EP1736545A3 (de) 2000-08-08 2007-03-28 ZymoGenetics, Inc. Lösliche Zcyctor 11 Cytokinrezeptoren
KR100447530B1 (ko) * 2001-08-14 2004-09-08 한국과학기술원 ＯｍｐＦ를 이용하여 목적 단백질을 대장균 세포외로분비생산하는 방법
PT1446489E (pt) 2001-10-15 2012-04-24 Engeneic Molecular Delivery Pty Ltd Minicélulas intactas, como vectores para a transferência de adn e terapia genética in vitro e in vivo
EP2130919A1 (de) 2001-11-05 2009-12-09 ZymoGenetics, Inc. IL-21-Antagonisten
WO2003054155A2 (en) * 2001-12-19 2003-07-03 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
RU2490276C2 (ru) 2002-01-18 2013-08-20 Займоджинетикс, Инк. Новый лиганд рецептора цитокина zcytor17
WO2004003140A2 (en) 2002-01-18 2004-01-08 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
CN1659274A (zh) 2002-04-19 2005-08-24 津莫吉尼蒂克斯公司 细胞因子受体
MXPA04012116A (es) 2002-06-07 2005-04-19 Zymogenetics Inc Uso del il-21 en cancer y otras aplicaciones terapeuticas.
WO2004078965A1 (ja) * 2003-03-05 2004-09-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 大腸菌における異種蛋白質の製造方法
US20040241677A1 (en) * 2003-05-29 2004-12-02 Lin Jeffrey S Techniques for automated diagnosis of cell-borne anomalies with digital optical microscope
ES2296423B1 (es) * 2003-07-31 2009-03-16 Consejo Sup. Investig. Cientificas Construccion de adn para la produccion de proteinas de fusion dimericas y sus aplicaciones.
JP4808157B2 (ja) 2003-08-07 2011-11-02 ザイモジェネティクス リミテッド ライアビリティ カンパニー Ｉｌ−２８およびｉｌ−２９の均一な調製物
EP1653995A1 (de) 2003-08-08 2006-05-10 Novo Nordisk A/S Interleukin-20 zur behandlung und diagnose von mit neovaskularization verbunden zuständen
DE602004029173D1 (de) 2003-10-10 2010-10-28 Novo Nordisk As Il-21-derivate
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
ATE501735T1 (de) 2003-12-09 2011-04-15 Engeneic Molecular Delivery Pty Ltd Gezielte genabgabe an nicht-phagozytische säugetierzellen über bakteriell erhaltene intakte minizellen
CA2558811A1 (en) 2004-03-08 2005-09-22 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
US7351689B2 (en) 2004-07-29 2008-04-01 Zymogenetics, Inc. Use of IL-28 and IL-29 to treat cancer and autoimmune disorders
EP1781784A2 (de) 2004-08-02 2007-05-09 BASF Plant Science GmbH Verfahren zur isolierung von transkriptionsterminationssequenzen
CN102921019B (zh) 2004-08-26 2015-04-01 恩杰内克分子递送有限公司 通过细菌性来源的完整小细胞向哺乳动物细胞递送功能性核酸
WO2006086396A2 (en) 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
EP3683230A1 (de) 2005-05-12 2020-07-22 ZymoGenetics, Inc. Zusammensetzungen und verfahren zur modulation von immunsystemreaktionen
WO2006130657A2 (en) * 2005-05-31 2006-12-07 Bristol-Myers Squibb Company Stereoselective reduction process for the preparation of pyrrolotriazine compounds
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
KR20080056714A (ko) * 2005-08-09 2008-06-23 지모제넥틱스, 인코포레이티드 ＴＡＣＩ―Ｉｇ 융합 분자를 사용하여 Ｂ―세포 악성종양을치료하는 방법
WO2007134326A2 (en) * 2006-05-15 2007-11-22 Ares Trading S.A. Methods for treating autoimmune diseases using a taci-ig fusion molecule
LT2712618T (lt) 2006-06-23 2017-02-27 Engeneic Molecular Delivery Pty Ltd. Vaistų, terapinių nukleorūgščių ir funkcinių nukleorūgščių tikslinis įvedimas į žinduolio ląsteles per nepažeistas žuvusias bakterines ląsteles
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8318664B2 (en) 2007-05-31 2012-11-27 Alize Pharma Sas Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
ES2538111T3 (es) * 2007-05-31 2015-06-17 Alizé Pharma SAS Grelina no acilada como agente terapéutico en el tratamiento de trastornos metabólicos
US7858759B2 (en) 2007-10-04 2010-12-28 Zymogenetics, Inc. Anti-zB7H6 antibody-drug conjugates
CN101918437B (zh) 2007-11-21 2013-08-14 罗斯基勒大学 具有冰结合活性的多肽
US20110027337A1 (en) * 2007-12-21 2011-02-03 Ifxa A/S Protease inhibitor
KR101720760B1 (ko) * 2008-01-25 2017-03-28 오르후스 우니베르시테트 Ｉｇｆｂｐ-4에 대한 ｐａｐｐ-ａ 활성의 선택적 엑소사이트 억제
JP5425180B2 (ja) 2008-03-27 2014-02-26 ザイモジェネティクス， インコーポレイテッド ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法
WO2009158696A1 (en) 2008-06-27 2009-12-30 Zymogenetics, Inc. SOLUBLE HYBRID Fcγ RECEPTORS AND RELATED METHODS
WO2010017383A1 (en) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
EP2580238A1 (de) 2010-06-09 2013-04-17 Zymogenetics, Inc. Dimere vstm3-fusionsproteine sowie zugehörige zusammensetzungen und verfahren
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
EP2583975A1 (de) * 2011-10-21 2013-04-24 Heinrich-Heine-Universität Düsseldorf Mittel und Verfahren zur Expression und Sekretion von Peptiden und Proteinen
CA2862149C (en) 2012-02-01 2022-07-26 Synthetic Genomics, Inc. Materials and methods for the synthesis of error-minimized nucleic acid molecules
US9862932B2 (en) 2012-07-24 2018-01-09 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
EP2890720B1 (de) 2012-08-30 2019-07-17 The General Hospital Corporation Zusammensetzungen und verfahren zur behandlung von krebs
AU2013312838B2 (en) 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
EP2990485B1 (de) * 2013-04-25 2019-09-11 Kaneka Corporation Fd-kettengen oder l-kettengen zur erhöhung der sekretionsmenge des antikörpers vom fab-typ
SI2997141T1 (sl) 2013-05-13 2023-04-28 Cellectis CD19 specifični himerni antigenski receptor in njegova uporaba
WO2014202089A2 (en) 2013-06-18 2014-12-24 Roskilde Universitet Variants of anti-freeze polypeptides
WO2015089280A1 (en) 2013-12-11 2015-06-18 The General Hospital Corporation Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
WO2015092024A2 (en) 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
TR201910814T4 (tr) 2014-03-19 2019-08-21 Cellectis Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri.
WO2015166056A1 (en) 2014-05-02 2015-11-05 Cellectis Cs1 specific multi-chain chimeric antigen receptor
US10752684B2 (en) 2014-07-29 2020-08-25 Cellectis ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapy
WO2016016343A1 (en) 2014-07-31 2016-02-04 Cellectis Ror1 specific multi-chain chimeric antigen receptor
WO2016034666A1 (en) 2014-09-04 2016-03-10 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
EP3250602A1 (de) 2015-01-26 2017-12-06 Cellectis T-zellenrezeptor-knockout-manipulierte immunzellen mit an cd123 bindenden chimären antigenrezeptoren zur behandlung von rezidivierenden/refraktären akuten myeloischen lymphomen oder blastischen plasmazytoiden dendritischen zellneoplasmen
TWI700298B (zh) 2015-04-13 2020-08-01 美商輝瑞股份有限公司 靶向ｂ細胞成熟抗原之嵌合型抗原受體類
EP3283529B1 (de) 2015-04-17 2023-06-07 The General Hospital Corporation Wirkstoffe, systeme und verfahren zur behandlung von krebs
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TW201706300A (zh) 2015-05-20 2017-02-16 瑟勒提斯公司 用於癌症免疫療法之抗－ｇｄ３專一性嵌合抗原受體
CN107969127B (zh) 2015-09-08 2022-09-06 赛瑞品股份有限公司 Apoa-1融合多肽及相关组合物和方法
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
BR112018014585A2 (pt) 2016-01-21 2018-12-11 Pfizer receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii
MA46469A (fr) 2016-10-06 2019-08-14 Engeneic Molecular Delivery Pty Ltd Minicellules bactériennes pour l'administration d'adjuvants d'acides nucléiques et leurs procédés d'utilisation
WO2018073394A1 (en) 2016-10-19 2018-04-26 Cellectis Cell death inducing chimeric antigen receptors
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018136163A2 (en) 2016-12-09 2018-07-26 Theripion, Inc. Tandem apoa-1 fusion polypeptides
CN110869046B (zh) 2017-03-31 2025-02-25 塞勒克提斯公司 通用型抗cd22嵌合抗原受体工程化的免疫细胞
CN110520196A (zh) 2017-04-19 2019-11-29 艾洛基治疗公司 改进的t细胞组合物和方法
PE20241587A1 (es) 2017-06-02 2024-08-01 Pfizer Receptores de antigenos quimericos que se dirigen a flt3
AU2018292181B2 (en) 2017-06-30 2025-04-10 Cellectis Cellular immunotherapy for repetitive administration
US11725060B2 (en) 2017-07-20 2023-08-15 Aptevo Reserch and Development LLC Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods
WO2019072824A1 (en) 2017-10-09 2019-04-18 Cellectis IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
EP3703689A1 (de) 2017-11-01 2020-09-09 Allogene Therapeutics, Inc. Modifizierte caspase-9 polypeptide und verfahren zu ihrer verwendung
SG11202005692WA (en) 2017-12-20 2020-07-29 Harbour Biomed Shanghai Co Ltd Antibodies binding ctla-4 and uses thereof
WO2019132765A1 (en) 2017-12-27 2019-07-04 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
US10150801B1 (en) 2017-12-27 2018-12-11 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
MX2020008183A (es) 2018-02-01 2020-09-22 Pfizer Anticuerpos especificos para cd70 y sus usos.
MX2020008184A (es) 2018-02-01 2020-09-22 Pfizer Receptores de antigeno quimericos dirigidos a cd70.
AU2019227979B2 (en) 2018-03-02 2024-09-05 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
US20210268028A1 (en) 2018-07-02 2021-09-02 Cellectis Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
US20220009993A1 (en) 2018-11-14 2022-01-13 Fundación Pública Andaluza Progreso Y Salud Polynucleotide for safer and more effective immunotherapies
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
MX2022001882A (es) 2019-08-12 2022-05-30 Aptevo Res & Development Llc Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
US10675332B1 (en) 2019-08-26 2020-06-09 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
WO2021040610A1 (en) 2019-08-26 2021-03-04 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
EP3882260A1 (de) * 2020-03-18 2021-09-22 NUMAFERM GmbH Fragmente von hlya und verwendungen davon
US12655229B2 (en) 2020-03-18 2026-06-16 Memorial Sloan Kettering Cancer Center Anti-ceramide antibodies
WO2022194375A1 (en) 2020-03-18 2022-09-22 Numaferm Gmbh Fusion proteins comprising gg repeat sequences
US12686725B2 (en) 2020-05-05 2026-07-21 Mythic Therapeutics, Inc. Anti-DLL3 antibodies and methods of use
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US20240293504A1 (en) 2020-06-22 2024-09-05 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and combinations for use in the treatment of cancer
WO2022020456A2 (en) 2020-07-21 2022-01-27 Allogene Therapeutics, Inc. Chimeric antigen receptors with enhanced signaling and activities and uses thereof
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
JP2023541705A (ja) 2020-09-21 2023-10-03 フンダシオン プブリカ アンダルーサ プログレソ イ サルー Ｔ細胞における生理学的発現のためのポリヌクレオチド
AU2021390501A1 (en) 2020-12-01 2023-06-29 Aptevo Research And Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
JP2024500189A (ja) 2020-12-21 2024-01-04 アロジーン セラピューティクス，インコーポレイテッド プロテアーゼ活性化ｃｄ４５ゲートｃａｒ
MX2023008809A (es) 2021-01-29 2023-08-04 Allogene Therapeutics Inc ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS.
EP4294916A2 (de) 2021-02-19 2023-12-27 Theripion, Inc. Dnase-fusionspolypeptide sowie zugehörige zusammensetzungen und verfahren
KR20230151518A (ko) 2021-03-04 2023-11-01 알로젠 테라퓨틱스 인코포레이티드 치료 세포를 동종이계 거부반응 및 활성화 유도된 세포 사멸로부터 보호하기 위한 FasL 발현 및 FasR 유전자 녹아웃
US20240228553A1 (en) 2021-03-18 2024-07-11 Numaferm Gmbh Fusion proteins comprising gg repeat sequences
EP4355358A1 (de) 2021-06-15 2024-04-24 Allogene Therapeutics, Inc. Selektives targeting von alloreaktiven wirtszellen cd70+ zur verlängerung der persistenz allogener car-t-zellen
EP4499680A1 (de) 2022-03-29 2025-02-05 Allogene Therapeutics, Inc. Chimäre schalterrezeptoren zur umwandlung von immunsuppressiven signalen in kostimulatorische signale
US20240042030A1 (en) 2022-07-29 2024-02-08 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
EP4339202A1 (de) 2022-09-16 2024-03-20 NUMAFERM GmbH Fusionsproteine mit gg-wiederholungssequenzen ii
CN120584137A (zh) 2023-01-06 2025-09-02 阿帕特夫研究和发展有限公司 双特异性pd-l1和cd40结合分子以及其用途
WO2024259220A1 (en) 2023-06-15 2024-12-19 Theripion, Inc. Pon3 and evolved pon1 fusion polypeptides
KR20260105764A (ko) 2023-10-30 2026-07-07 알로젠 테라퓨틱스 인코포레이티드 조작된 세포

Also Published As

Publication number Publication date
DK13788A (da) 1988-03-15
AU7392387A (en) 1987-12-01
DK13788D0 (da) 1988-01-13
GB2197324B (en) 1990-04-11
AU600949B2 (en) 1990-08-30
EP0267224B1 (de) 1992-09-16
JPS63503274A (ja) 1988-12-02
WO1987006953A1 (en) 1987-11-19
DE3781765D1 (de) 1992-10-22
GB2197324A (de) 1988-05-18
EP0267224A1 (de) 1988-05-18
DE3781765T2 (de) 1993-04-22
GB8611832D0 (en) 1986-06-25
GB8800141D0 (en) 1988-03-02
US5143830A (en) 1992-09-01

Similar Documents

Publication Publication Date Title
DE3781765D1 (de) Verfahren zur herstellung eines polypeptides.
ATE46536T1 (de) Verfahren zur herstellung von reifen proteinen in wirtzellen von wirbeltieren.
DE69018920D1 (de) Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions-kassetten, transformierte hefen und verfahren zur herstellung dieser proteine.
DE69128285D1 (de) Expression rekombinanter polypeptide mit verbesserter möglichkeit zur reinigung
DE3587422D1 (de) Fuer ein hirudinaehnliches protein kodierende dns-sequenz und verfahren zur herstellung eines solchen proteins.
ATE352617T1 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
IL98024A0 (en) Cd44-surface proteins,dna-sequences coding therefor,polypeptides coded by said dna sequences and diagnostic compositions containing the same
NZ222856A (en) Equine interferon gamma (eq ifn alpha), dna sequences for its recombinant production and monoclonal antibodies thereto
DE69939330D1 (de) Wachstumsfaktor-homologe zvegf-3
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
JPS6420095A (en) Polypeptide having anti-blood coagulating action
DE3585084D1 (de) Verfahren zur reinigung eines proteins.
ATE154362T1 (de) Verfahren zur herstellung von pai-2
ATE253639T1 (de) Verfahren zur herstellung von peptiden
DE3877035D1 (de) Gentechnologisches verfahren zur herstellung von polypeptiden.
ATE169333T1 (de) Verfahren zur herstellung rekombinanter polypeptide mit schweine-wachstumshormonaktivität
MXPA01011158A (es) Factor de crecimiento homologo zvegf4.
DE3873273D1 (de) Verfahren zur selektiven spaltung von fusionsproteinen.
BR1100940A (pt) Polipeptìdeos puros, sequências adn, molécula adn recombinada, célula hospedeira, processo de manipulação genética para produção de polipeptìdeo, e, uso de um polipeptìdeo
ATE139538T1 (de) Verfahren zur selektiven spaltung von fusionsproteinen
ATE110775T1 (de) Verfahren zur herstellung von hirudin.
ATE91303T1 (de) Verfahren zur herstellung von peptiden durch spezifische spaltung von gentechnisch gewonnenen fusionsproteinen mit collagenasen.
ATE83799T1 (de) Verfahren und produkte zur leichten mikrobiologischen expression von dns-sequenzen.
DE3470747D1 (en) Immune interferon and method for its purification

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee